Esophageal Squamous Cell Carcinoma Clinical Trials in New Haven, Connecticut

3 studies are recruiting for esophageal squamous cell carcinoma in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale University Cancer Center, New Haven, Connecticut
    Locations
    16 in total
    Run by
    EvolveImmune United, Inc

    See if you can join NCT07217171 on ClinicalTrials.gov

  2. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Smilow Cancer Hospital - Yale New Haven Health, New Haven, Connecticut
    Locations
    31 in total
    Run by
    Pfizer

    See if you can join NCT07090499 on ClinicalTrials.gov

  3. A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale Comprehensive Cancer Center, New Haven, Connecticut
    Locations
    41 in total
    Run by
    Alentis Therapeutics AG

    See if you can join NCT06747585 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.